71 completed, 28 recruiting, 20 active not recruiting, 16 unknown. 71 Not applicable, 29 Phase 1, 27 Phase 2, 14 Phase 3, 6 Phase 4.
Follow this condition Literature Review of Overweight or Obesity trials Research Report on Overweight or Obesity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SYH2092 Injection in Healthy Participants SYH2092 Injection, Placebo - Overweight or Obesity | Phase 1 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 46 | 2026-09-30 | 2026-08-20 |
| Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes. SYH2069 Injection, SYH2069 Injection Placebo - Overweight or Obesity | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 360 | 2026-09-01 | 2026-09-04 |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes Olatorepatide, Placebo - Overweight or Obesity | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 360 | 2026-07-28 | 2026-10-13 |
| Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain JITAI Combined with psychological intervention, Active Control - Overweight or Obesity | Not applicable | Recruiting | ORI Community and Evaluation Services | 120 | 2026-07-14 | 2026-08-11 |
| A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity HRS-4729 Injection, HRS-4729 Injection;, HRS-4729 Injection Placebo - Overweight or Obesity | Phase 2 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 252 | 2026-07-01 | 2026-07-08 |
| Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity REGN20934, Placebo - Overweight or Obesity | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2026-06-29 | 2026-09-25 |
| Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation Metformin, Antidepressant Therapy - Depression, Depressive Disorder | Not applicable | Recruiting | Riphah International University | 200 | 2026-06-17 | 2026-08-07 |
| Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life App - Diabetes Type 2, Overweight or Obesity | Not applicable | Recruiting | Yale University | 20 | 2026-06-04 | 2026-06-17 |
| A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity PF-08653945, PF-08653944, Placebo - Overweight, Obesity | Phase 2 | Active not recruiting | Pfizer | 940 | 2026-05-11 | 2026-10-13 |
| A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants SYH2082 Injection, Placebo - Overweight or Obesity | Phase 1 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 44 | 2026-04-14 | 2026-04-16 |
| A Study of SYH2082 Injection in Healthy Participants SYH2082 Injection, Placebo - Overweight or Obesity | Phase 1 | Active not recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 50 | 2026-04-13 | 2026-07-30 |
| A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight RO7795081, Placebo - Healthy Volunteers, Overweight or Obesity | Phase 1 | Active not recruiting | Hoffmann-La Roche | 30 | 2026-03-30 | 2026-08-10 |
| Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women Resistance Training - Overweight or Obesity, Prediabetes or Diabetes | Not applicable | Active not recruiting | University of Alabama at Birmingham | 37 | 2026-03-19 | 2026-10-14 |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US Olatorepatide, Placebo - Overweight or Obesity | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 120 | 2026-03-16 | 2026-06-17 |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight Eloralintide, Placebo - Osteoarthritis, Overweight or Obesity | Phase 3 | Recruiting | Eli Lilly and Company | 900 | 2026-02-09 | 2026-10-08 |
| A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE） MDR-001, Placebo - Overweight or Obesity | Phase 3 | Not yet recruiting | MindRank AI Ltd | 738 | 2026-02-01 | 2025-12-22 |
| Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss GZR18 injection, Placebo - Overweight or Obesity | Phase 3 | Recruiting | Gan & Lee Pharmaceuticals. | 500 | 2026-01-22 | 2026-03-11 |
| A Study of SYH2069 Injection in Healthy Participants SYH2069 Injection, Placebo - Overweight or Obesity, Diabetes | Phase 1 | Active not recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 104 | 2026-01-10 | 2026-07-30 |
| A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants BGM1812, Placebo - Overweight or Obesity | Phase 1 | Completed | BrightGene Bio-Medical Technology Co., Ltd. | 60 | 2025-12-05 | 2026-10-15 |
| Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects HRS-9531 Tablet - Overweight or Obesity | Phase 1 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 168 | 2025-10-15 | 2025-11-17 |
Showing 20 of 152. Sign in to see all of them.
Obesity (152) · Overweight (152) · Diabetes Mellitus, Type 2 (16) · Motor Activity (11) · Body Weight (10) · Hypertension (10) · Weight Loss (10) · Prediabetic State (9) · Diabetes Mellitus (7) · Cardiovascular Diseases (5) · Body Weight Changes (4) · Insulin Resistance (4) · Metabolic Syndrome (4) · Neoplasms (4) · Nutrition Disorders (4)
Pathological Conditions, Signs and Symptoms (152) · Signs and Symptoms (152) · Nutritional and Metabolic Diseases (151) · Overnutrition (150) · Nutrition Disorders (148) · Body Weight (142) · Metabolic Diseases (36) · Glucose Metabolism Disorders (32) · Endocrine System Diseases (26) · Behavior (24) · Diabetes Mellitus (19) · Cardiovascular Diseases (12) · Vascular Diseases (12) · Body Weight Changes (10) · Hyperinsulinism (8)
semaglutide (6) · Exercise (5) · orforglipron (4) · Bupropion (3) · Diet (3) · Tirzepatide (3) · Acetaminophen (2) · Naltrexone (2) · Probiotics (2) · Propofol (2) · Resistance Training (2) · bupropion hydrochloride, naltrexone hydrochoride drug combination (2) · remimazolam (2) · Acupuncture, Ear (1) · Amyloid (1)
Eli Lilly and Company (10) · Fujian Shengdi Pharmaceutical Co., Ltd. (6) · University of Chicago (4) · Yale University (4) · BrightGene Bio-Medical Technology Co., Ltd. (3) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (3) · CSPC Ouyi Pharmaceutical Co., Ltd. (3) · Clinical Nutrition Research Center, Illinois Institute of Technology (3) · Empros Pharma AB (3) · Pfizer (3) · Regeneron Pharmaceuticals (3) · University of Southern California (3) · Beijing QL Biopharmaceutical Co.,Ltd (2) · Green Beat (2) · Novo Nordisk A/S (2)
United States (66) · China (40) · Spain (9) · Canada (6) · Puerto Rico (6) · United Kingdom (6) · Argentina (5) · Australia (5) · Denmark (5) · Germany (5) · Japan (5) · Mexico (5) · Taiwan (5) · Belgium (4) · Brazil (4)
Genevieve F Dunton, PhD MPH (3) · Janet A Lydecker, PhD (2) · Manfred Lamprecht, PhD (2) · Silvana Pannain, MD (2) · Aaron Lazorwitz, MD (1) · Adnin Zaman, MD (1)
PMID 12147930, PMID 12682080, PMID 14704836, PMID 15173128, PMID 15470483, PMID 15788708, PMID 16935461, PMID 17449506, PMID 17490954, PMID 17890487, PMID 18556187, PMID 18586647, PMID 19139321, PMID 1987006, PMID 19934192, PMID 20194225, PMID 21071956, PMID 22171802, PMID 22364888, PMID 22907057, PMID 23936079, PMID 24192084, PMID 24244395, PMID 24338487, PMID 25379623, PMID 26482149, PMID 26498129, PMID 27037767, PMID 27160199, PMID 27636835, PMID 27923415, PMID 29507099, PMID 30122305, PMID 30754681, PMID 31196460, PMID 31239546, PMID 31540146, PMID 33028352, PMID 33315809, PMID 33567185, PMID 34430840, PMID 35441470, PMID 35635643, PMID 35724304, PMID 36200477, PMID 36247927, PMID 36656819, PMID 36801984, PMID 36876594, PMID 37726820
2023 (3), R01CA272933 (2), 2017 (1), 2025 (1), P20GM144269 (1), P50MD017338 (1), R01CA268017 (1), R01DK120312 (1), R01DK130900 (1), R01DK136623 (1), R01MD015724 (1), R03CA292977 (1), UG3HL141729-01A1 (1)